DekaBank Deutsche Girozentrale Has $277,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DekaBank Deutsche Girozentrale boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.0% in the first quarter, HoldingsChannel reports. The firm owned 24,700 shares of the company’s stock after purchasing an additional 1,610 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Teva Pharmaceutical Industries were worth $277,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ayalon Holdings Ltd. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth approximately $26,000. Freedman Financial Associates Inc. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $38,000. Safeguard Investment Advisory Group LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $42,000. Koshinski Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $303,000. Finally, Carolina Wealth Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 13,261.7% in the first quarter. Carolina Wealth Advisors LLC now owns 6,280 shares of the company’s stock worth $72,000 after purchasing an additional 6,233 shares in the last quarter. Institutional investors and hedge funds own 51.20% of the company’s stock.

Shares of Teva Pharmaceutical Industries stock opened at $10.57 on Friday. The stock has a fifty day simple moving average of $10.79 and a 200 day simple moving average of $10.67. Teva Pharmaceutical Industries Limited has a 12-month low of $8.44 and a 12-month high of $13.30. The company has a market capitalization of $11.54 billion, a P/E ratio of -2.87, a price-to-earnings-growth ratio of 0.87 and a beta of 1.49. The company has a current ratio of 1.00, a quick ratio of 0.63 and a debt-to-equity ratio of 2.22.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, April 28th. The company reported $0.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.08. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. The business had revenue of $3.98 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the prior year, the company posted $0.76 earnings per share. Teva Pharmaceutical Industries’s revenue was down 8.6% compared to the same quarter last year. On average, analysts predict that Teva Pharmaceutical Industries Limited will post 2.42 EPS for the current year.

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 127,244 shares of the business’s stock in a transaction on Tuesday, March 16th. The stock was sold at an average price of $11.22, for a total value of $1,427,677.68. Following the transaction, the insider now owns 20,598 shares of the company’s stock, valued at $231,109.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP David Matthew Stark sold 37,884 shares of the business’s stock in a transaction on Tuesday, May 11th. The stock was sold at an average price of $10.22, for a total value of $387,174.48. Following the completion of the transaction, the vice president now directly owns 40,858 shares in the company, valued at approximately $417,568.76. The disclosure for this sale can be found here. Corporate insiders own 0.56% of the company’s stock.

A number of equities research analysts have weighed in on TEVA shares. TheStreet upgraded Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a report on Monday, April 5th. JPMorgan Chase & Co. restated a “hold” rating and set a $10.00 price objective on shares of Teva Pharmaceutical Industries in a report on Sunday, March 14th. Finally, UBS Group restated a “neutral” rating and set a $11.00 price objective (down previously from $15.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $11.58.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Momentum Indicators

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.